|Filed Under:||Business & Finance / Investing|
|Posts on Regator:||204004|
|Posts / Week:||860.1|
|Archived Since:||February 15, 2010|
Here are five cant-miss quotes from HCA Holdings, Inc.'s second-quarter conference call.
The device will be sold as a stand-alone add-on for Xbox One.
Well off their 52-week highs, these three value stocks might be poised for a big rebound.
Key highlights from the company's latest conference call with analysts.
Let’s take a closer look at GoPro’s three key weaknesses.
A Home Depot data breach could weight on the retailer brand and its performance.
We're taking a 360-degree look at the leading consumer robotics company. This piece explores the bear argument thesis.
What could derail Union Pacific's stock? Here are a few things to watch out for.
Rumors are heating up that Apple will beat Facebook to the punch on mobile payments.
This company provides a number of chips for Apple's MacBook Pro series of laptops.
With global expansion of Advate and European approval of a $370 million new production facility in Singapore, Baxter is diving headfirst into its future. Here's why executives believe this company is about to fundamentally change for the better.
Novartis LCZ696 may give doctors the first significant high blood pressure drug approved in decades if regulators give it the okay next year.
Microsoft's Windows Phone continues to lose ground to Google's Android.
Disney parks have the most visitors and Disney Shanghai is in the works.
Letting tax considerations drive your investment decisions can be risky, but it can also cut your tax bill.
PotashCorp shares nosedived in July last year. They're finally starting to get back on track.
Occidental is ramping up production, thanks to its prime asset in the Permian Basin. Here are a few things management wants investors to keep in mind going forward.
Here is what you need to know about the latest big analyst upgrade that is sending shares to new highs today.
The company's planned acquisition of Prestige brands Regents Seven Seas and Oceania delivers access to well-heeled cruisers
Exelixis' stock is among today's biggest losers after its late-stage prostate cancer trial failed to meet its primary endpoint. See what shareholders should be focused on going forward.